WuXi Biologics and Prima Biomed Ltd. have signed an agreement to form a strategic biologics development and manufacturing partnership. Prima is developing IMP321, a recombinant soluble LAG-3 protein and other LAG-3 related products for use in oncology.

WuXi Biologics will be the exclusive clinical manufacturer for IMP321 worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong, where rights are retained by Prima’s development partner, Eddingpharm. WuXi Biologics will also be Prima’s preferred partner to manufacture potential new products.

IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy, is currently in Phase II development in Europe.
Prima BioMed chief executive officer, Mr. Marc Voigt said, “Securing the future supply of IMP321 is a key component of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our strategic partnership.”

“We are honored to play a critical role to enable biotech and pharma companies to realize commercialization via WuXi’s innovative biomanufacturing network based on state-of-the-art disposable manufacturing technology,” said Dr. Chris Chen, chief executive officer of WuXi Biologics, “WuXi Biologics is committed to producing the highest quality product to enable robust global supply of this potential biologics to patients worldwide.”